SCHEMBL6895896

SCHEMBL6895896

CC(=O)SCCN(CCc1ccc(F)cc1)C(=O)N[C@@H](C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.39
MME P08473 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PPARG P37231 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
MMP2 P08253 1/20 0.37
MAPK1 P28482 1/20 0.37
TSHR P16473 2/20 0.36
TAAR1 Q96RJ0 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
POLB P06746 1/20 0.35
ACE P12821 1/20 0.35
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27560035 1.00 LPAR1 (0.39) LPAR1MMEMEN1KMT2APPARG
SCHEMBL6889315 0.94 LPAR1 (0.43) LPAR1MMEMEN1KMT2APPARG
SCHEMBL27559957 0.90 LPAR1 (0.42) LPAR1MEN1KMT2APPARGPPARD
SCHEMBL6890752 0.90 LPAR1 (0.42) LPAR1MEN1KMT2APPARGPPARD
SCHEMBL27543517 0.90 LPAR1 (0.48) LPAR1MMEMEN1KMT2ATSHR
SCHEMBL6891444 0.90 LPAR1 (0.48) LPAR1MMEMEN1KMT2ATSHR
SCHEMBL6898352 0.90 LPAR1 (0.48) LPAR1MMEMEN1KMT2ATSHR
SCHEMBL27538379 0.89 HSD17B10 (0.40) LPAR1MEN1KMT2APPARGPPARD
SCHEMBL6896867 0.89 HSD17B10 (0.40) LPAR1MEN1KMT2APPARGPPARD
SCHEMBL6891035 0.88 PPARG (0.45) LPAR1MMEMEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH LPAR1 4229/4885MME 1516/4885MEN1 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.